Comparative Study of Two Recombinant Human Erythropoietin Products in Chronic Kidney Disease Patients

Launched by MEGALABS · Apr 1, 2024

Keywords

ClinConnect Summary

This clinical trial is studying two different medications, Megalabs® recombinant human alfa epoetin and Epogen®, to see how well they treat anemia in patients with chronic kidney disease who are on hemodialysis (a treatment that helps filter waste from the blood). The goal is to find out if Megalabs® is as effective and safe as Epogen® for managing this condition.

If you or a family member has stage V chronic kidney disease and is currently receiving hemodialysis, you may be eligible to participate in this study. Participants will be randomly assigned to receive one of the two medications, and neither the participants nor the healthcare providers will know which medication is being given to ensure a fair comparison. It's important to note that individuals with severe other health issues or certain specific medical histories will not be able to join the trial. If you decide to participate, you will be monitored closely for how well the treatment works and any possible side effects.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Stage V Chronic kidney disease undergoing hemodialysis
• Exclusion Criteria:
• • Lack of consent to participate in the trial, other severe chronic disease, history of pure red cell aplasia, existence of anti erythropoietin antibodies